{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:51Z","timestamp":1781636091271,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      A simple suspension method is used in medical practice to administer several orexin receptor antagonists for patients with dysphagia; however, detailed suspension and passage through catheter evaluations have not been performed. Therefore, to safely administer orexin receptor antagonists using the simple suspension method in patients with dysphagia, this study evaluated the disintegration, suspension, passage through the catheter, and drug recovery after passage of Belsomra\n                      <jats:sup>\u00ae<\/jats:sup>\n                      20\u2009mg (suvorexant), Dayvigo\n                      <jats:sup>\u00ae<\/jats:sup>\n                      10\u2009mg (lemborexant), and Quviviq\n                      <jats:sup>\u00ae<\/jats:sup>\n                      50\u2009mg (daridorexant) tablets through a catheter.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Disintegration and suspension of Belsomra\n                      <jats:sup>\u00ae<\/jats:sup>\n                      20 mg, Dayvigo\n                      <jats:sup>\u00ae<\/jats:sup>\n                      10 mg, and Quviviq\n                      <jats:sup>\u00ae<\/jats:sup>\n                      50 mg tablets, and passage through the catheter were visually confirmed. Drug recovery after passage through the catheter was quantified using liquid chromatography-mass spectrometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this study, there was no disintegration and suspension of Belsomra\n                      <jats:sup>\u00ae<\/jats:sup>\n                      20 mg tablets. However, Dayvigo\n                      <jats:sup>\u00ae<\/jats:sup>\n                      10 mg and Quviviq\n                      <jats:sup>\u00ae<\/jats:sup>\n                      50 mg tablets demonstrated disintegration and suspension, including passage through the catheter after rapid and complete disintegration. Drug recovery after catheter passage was &gt;80% for Dayvigo\n                      <jats:sup>\u00ae<\/jats:sup>\n                      10 mg without flushing and for Quviviq\n                      <jats:sup>\u00ae<\/jats:sup>\n                      50 mg after two flushes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      As the disintegration and suspension properties of Belsomra\n                      <jats:sup>\u00ae<\/jats:sup>\n                      20 mg tablet could not be confirmed, the conventional simple suspension method is not suitable for this product. However, Dayvigo\n                      <jats:sup>\u00ae<\/jats:sup>\n                      10 mg and Quviviq\n                      <jats:sup>\u00ae<\/jats:sup>\n                      50 mg tablets showed potential suitability for the simple suspension method.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00553-7","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T15:15:35Z","timestamp":1771082135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigation of a simple suspension method for orexin receptor antagonist tablets"],"prefix":"10.1186","volume":"12","author":[{"given":"Kazuhiro","family":"Hada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouyou","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"553_CR1","doi-asserted-by":"crossref","unstructured":"Nagano A, Onaka M, Maeda K, Ueshima J, Shimizu A, Ishida Y, et al. Prevalence and characteristics of the course of dysphagia in hospitalized older adults. Nutrients. 2023;15.","DOI":"10.3390\/nu15204371"},{"key":"553_CR2","doi-asserted-by":"publisher","first-page":"105113","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105113","volume":"29","author":"PP Meng","year":"2020","unstructured":"Meng PP, Zhang SC, Han C, Wang Q, Bai GT, Yue SW. The occurrence rate of swallowing disorders after stroke patients in Asia: a PRISMA-Compliant systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020;29:105113.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"553_CR3","doi-asserted-by":"crossref","unstructured":"Takahashi K, Amemiya K, Nakatsuka M, Nakamura K, Kasai M, Meguro K. Impaired eating and swallowing function in older adults in the community: the kurihara project. Int J Environ Res Public Health. 2019;16.","DOI":"10.3390\/ijerph16204040"},{"key":"553_CR4","doi-asserted-by":"crossref","unstructured":"Madsen G, Kristoffersen SM, Westergaard MR, Gj\u00f8dvad V, Jessen MM, Melgaard D. Prevalence of swallowing and eating difficulties in an elderly postoperative hip fracture population-a multi-center-based pilot study. Geriatrics (Basel). 2020;5.","DOI":"10.3390\/geriatrics5030052"},{"key":"553_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5112\/jjlp.54.167","volume":"54","author":"T Ohmae","year":"2013","unstructured":"Ohmae T. Changes in swallowing functions with aging. The Jpn J Logopedics Phoniatrics. 2013;54:167\u201373.","journal-title":"The Jpn J Logopedics Phoniatrics"},{"key":"553_CR6","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1007\/s11096-013-9836-2","volume":"35","author":"J Marquis","year":"2013","unstructured":"Marquis J, P. SM, Payot V, C. CA, Bugnon O, E. HK, et al. Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. Int J Clin Pharm. 2013;35:1130\u201336.","journal-title":"Int J Clin Pharm"},{"key":"553_CR7","first-page":"115","volume":"2","author":"S Dogra","year":"2022","unstructured":"Dogra S, Shah I, Upadhyay U. Tablets: most popular dosage form in the pharmaceutical industry. The most popular pharmaceutical dosage form. Tablet. 2022;2:115\u201321.","journal-title":"Tablet"},{"key":"553_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40266-023-01056-y","volume":"40","author":"A Blaszczyk","year":"2023","unstructured":"Blaszczyk A, Brandt N, Ashley J, Tuders N, Doles H, Stefanacci RG. Crushed tablet administration for patients with dysphagia and enteral feeding: challenges and considerations. Drugs Aging. 2023;40:895\u2013907.","journal-title":"Drugs Aging"},{"key":"553_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00455-021-10280-w","volume":"37","author":"K Kunieda","year":"2022","unstructured":"Kunieda K, Kurata N, Yoshimatsu Y, Ohno T, Shigematsu T, Fujishima I. A safe way to administer drugs through a nutrition tube-the simple suspension method. Dysphagia. 2022;37:318\u201322.","journal-title":"Dysphagia"},{"key":"553_CR10","first-page":"160","volume":"40","author":"Y Yokoyama","year":"2014","unstructured":"Yokoyama Y, Hada K, Miyazaki M, Yano K, Yamada K. Development of the administration route of morphine hydrochloride tablets by simple suspension method. Iryouyakugaku. 2014;40:160\u201364.","journal-title":"Iryouyakugaku"},{"key":"553_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0167-4943(99)00054-0","volume":"30","author":"Y Ito","year":"2000","unstructured":"Ito Y, Tamakoshi A, Yamaki K, Wakai K, Kawamura T, Takagi K, et al. Sleep disturbance and its correlates among elderly Japanese. Arch Gerontol Geriatr. 2000;30:85\u2013100.","journal-title":"Arch Gerontol Geriatr"},{"key":"553_CR12","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1002\/pcn5.113","volume":"2","author":"K Usui","year":"2023","unstructured":"Usui K, Kikuchi D, Otsuka N, Miyagi K, Ouchi R, Watanabe T, et al. Hypnotic prescriptions in Japan may be shifting from benzodiazepine receptor agonists to other types of hypnotics, melatonin receptor agonists, and orexin receptor antagonists. PCN Rep. 2023;2:e113.","journal-title":"PCN Rep"},{"key":"553_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1017\/S1092852916000225","volume":"21","author":"SM Stahl","year":"2016","unstructured":"Stahl SM. Mechanism of action of suvorexant. CNS Spectr. 2016;21:215\u201318.","journal-title":"CNS Spectr"},{"key":"553_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12793\/tcp.2024.32.e5","volume":"32","author":"WJ Kim","year":"2024","unstructured":"Kim WJ, Kim HS. Emerging and upcoming therapies in insomnia. Transl Clin Pharmacol. 2024;32:1\u201317.","journal-title":"Transl Clin Pharmacol"},{"key":"553_CR15","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/10600280221143794","volume":"57","author":"J Park","year":"2023","unstructured":"Park J, Kp RPD, Dw CPD. Daridorexant: comprehensive review of a New oral agent for the treatment of insomnia. Ann Pharmacother. 2023;57:1076\u201387.","journal-title":"Ann Pharmacother"},{"key":"553_CR16","unstructured":"Kurata N, Ishida S. Simple suspension method manual. Jiho. 2021;2."},{"key":"553_CR17","first-page":"10","volume":"47","author":"H Sawada","year":"2021","unstructured":"Sawada H, Terakawa N, Nishimura N, Kogure A, Tachiki H, Oita A. Study on the Nasogastric tube passage and the stability of active ingredients in a simple suspension method of oral drugs in combination with multiple drugs. Iryouyakugaku. 2021;47:10.","journal-title":"Iryouyakugaku"},{"key":"553_CR18","doi-asserted-by":"publisher","first-page":"113359","DOI":"10.1016\/j.jpba.2020.113359","volume":"187","author":"Y Mano","year":"2020","unstructured":"Mano Y, Ueno T, Hotta K. Establishment of a simultaneous assay for lemborexant, a novel dual orexin receptor antagonist, and its three metabolites, and its application to a clinical protein binding study. J Pharm Biomed Anal. 2020;187:113359.","journal-title":"J Pharm Biomed Anal"},{"key":"553_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jat\/bkz083","volume":"44","author":"B Skillman","year":"2020","unstructured":"Skillman B, Kerrigan S. Identification of suvorexant in blood using LC-MS-MS: important considerations for matrix effects and quantitative interferences in targeted assays. J Anal Toxicol. 2020;44:245\u201355.","journal-title":"J Anal Toxicol"},{"key":"553_CR20","doi-asserted-by":"publisher","first-page":"122265","DOI":"10.1016\/j.jchromb.2020.122265","volume":"1152","author":"B Skillman","year":"2020","unstructured":"Skillman B, Kerrigan S. Drug-mediated ion suppression and mitigation of interferences using liquid chromatography-quadrupole\/time of flight mass spectrometry (LC-Q\/TOF-MS) and liquid chromatography tandem mass spectrometry (LC-MS\/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1152:122265.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"553_CR21","doi-asserted-by":"publisher","first-page":"110307","DOI":"10.1016\/j.forsciint.2020.110307","volume":"312","author":"B Skillman","year":"2020","unstructured":"Skillman B, Kerrigan S. CYP450-mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens. Forensic Sci Int. 2020;312:110307.","journal-title":"Forensic Sci Int"},{"key":"553_CR22","doi-asserted-by":"crossref","unstructured":"Hada K, Murata Y, Ohi Y, Hashimoto S, Watanabe H, Ozeki K, et al. Involvement of orexin nerves in early stage of Alzheimer\u2019s disease model mice and preventive effect of orexin receptor antagonists. BioRxiv. 2025.","DOI":"10.1101\/2025.01.28.635390"},{"key":"553_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4274\/tjps.74946","volume":"14","author":"A Kumar","year":"2017","unstructured":"Kumar A, Saharan VA. A comparative study of different proportions of superdisintegrants: formulation and evaluation of orally disintegrating tablets of Salbutamol sulphate. Turk J Pharm Sci. 2017;14:40\u201348.","journal-title":"Turk J Pharm Sci"},{"key":"553_CR24","first-page":"12","volume":"22","author":"ED Antari","year":"2021","unstructured":"Antari ED, Kuncahyo I, Sulaiman TNS. Review of the use of croscarmellose sodium and crospovidone superdisintegrants in orally disintegrating tablets (ODT). Int J Pharm Pharm Res. 2021;22:12.","journal-title":"Int J Pharm Pharm Res"},{"key":"553_CR25","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1002\/jps.24362","volume":"104","author":"F Kesisoglou","year":"2015","unstructured":"Kesisoglou F, Hermans A, Neu C, Yee KL, Palcza J, Miller J. Development of in vitro-in vivo correlation for amorphous solid dispersion immediate-release suvorexant tablets and application to clinically relevant dissolution specifications and In-process controls. J Pharm Sci. 2015;104:2913\u201322.","journal-title":"J Pharm Sci"},{"key":"553_CR26","first-page":"7","volume":"46","author":"M Oda","year":"2020","unstructured":"Oda M, Furuto Y, Ichimura Y, Mori M, Takahashi M, Saitoh H. Stability of suvorexant (Belsomra\u00ae) tablets in one-dose package. Iryouyakugaku. 2020;46:7.","journal-title":"Iryouyakugaku"},{"key":"553_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3109\/03639045.2011.621432","volume":"38","author":"SY Jung","year":"2012","unstructured":"Jung SY, Kim DW, Seo YG, Woo JS, Yong CS, Choi HG. Development of sildenafil-loaded orally disintegrating tablet with new lactate salt. Drug Dev Ind Pharm. 2012;38:635\u201341.","journal-title":"Drug Dev Ind Pharm"},{"key":"553_CR28","doi-asserted-by":"publisher","first-page":"16352","DOI":"10.1038\/srep16352","volume":"5","author":"JS Koner","year":"2015","unstructured":"Koner JS, Rajabi-Siahboomi A, Bowen J, Perrie Y, Kirby D, Mohammed AR. A holistic multi evidence approach to study the fragmentation behaviour of crystalline mannitol. Sci Rep. 2015;5:16352.","journal-title":"Sci Rep"},{"key":"553_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/10837450.2017.1363775","volume":"23","author":"A ElShaer","year":"2018","unstructured":"ElShaer A, Al-Khattawi A, Mohammed AR, Warzecha M, Lamprou DA, Hassanin H. Understanding the compaction behaviour of low-substituted HPC: macro, micro, and nano-metric evaluations. Pharm Dev Technol. 2018;23:442\u201353.","journal-title":"Pharm Dev Technol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00553-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00553-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00553-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:17:06Z","timestamp":1781633826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00553-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00553-7","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}